ArticleFrontiers in oncology2025
Complete blood count parameters as potential predictive factors of brain metastases in lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations of three immune inflammatory markers with the risk of brain metastasis from lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- The immune microenvironment of the central nervous system and neuromodulation: new perspectives in lung cancer brain metastases research.Frontiers in immunology · 2026Review
- Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- Danggui Buxue Decoction attenuates 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung cancer growth in A/J mice by suppressing HIF-1α/VEGF-mediated angiogenesis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brain metastases are common and devastating complication of the lung cancer (LC) but predictive biomarkers for their risk are still lacking. Objectives: To analyze the relationships between complete blood count (CBC)-based and selected biochemical indices and occurrence of brain metastases in patients diagnosed with LC. Patients and methods: The study was based on retrospective analysis of medical records of 217 patients diagnosed with LC and undergoing follow-up in one specialist center. Clinical and laboratory data on admission were determined, including: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), neutrophil-to-platelet ratio (NPR) and red cell distribution width-to-platelet ratio (RPR) and selected biochemical parameters. Relationships were evaluated between these parameters and occurrence of brain metastases, other distant metastases and death within 12 months of follow-up. Results: 168 patients had the follow-up data for 6 months, and 128 - for 12 months. Brain metastases were detected in 41 patients and 1-year mortality rate was 17.61%. Patients who developed brain metastases during 12 months had significantly higher baseline NLR (4.66 vs 2.75, p<0.001), PLR (170.83 vs 142.42, p=0.03) and lower LMR (1.61 vs 2.33, p=0.008).In univariate analysis, higher leukocyte count (HR 1.08, p=0.016), neutrophil count (HR 1.11, p=0.0036), NLR (HR 1.09, p=0.005), d-dimer levels (HR 1.0002, p=0.0043), and lower LMR (HR 0.67, p=0.018) were significantly associated with the risk of developing brain metastases. Liver metastases were associated with lower LMR (1.69 vs 2.29, p=0.04), while metastases to the other lung - with lower PLR (126.52 vs 161.8, p=0.02) and higher LMR (2.51 vs 1.96, p=0.02) and RPR (0.184 vs 0.154, p=0.03). No significant relationships were found between CBC-based indices and mortality. Conclusions: CBC-based indices could be useful and easily accessible predictive markers of brain metastases in the patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.